Long only, deep value, special situations

CytRx's Aldoxorubicin's Potential Is Underestimated, Creating A Buying Opportunity

Investing in early stage biotech companies calls for a lot of understanding in regard to the processes related to drug testing and approval, and so is a unique challenge. Clearly, there is a stage to invest with less risk once a drug has been approved and the revenue picture emerges. However, there is significantly more money made by taking positions early in companies with significant and clear potential. Although this involves more risk, a prudent selection out of all that is available, followed by diversifying the exposure of this at-risk-money between companies within this sector can lead to significant investment profits. In fact, for my own portfolio during 2013, I have regrets only about one biotech that I screened, bought...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details